Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000935932
Ethics application status
Approved
Date submitted
30/08/2011
Date registered
31/08/2011
Date last updated
31/08/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
Clinical pharmacokinetics of metformin in Australian Aboriginal and Torres Strait Islanders
Query!
Scientific title
A study of factors affecting the concentrations of metformin in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes
Query!
Secondary ID [1]
262962
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1123-9802
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 diabetes
270685
0
Query!
Condition category
Condition code
Metabolic and Endocrine
270859
270859
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Australian Aboriginal patients who are taking metformin for their type 2 diabetes are required to provide a minimum of 1 blood sample and a maximum of 6 blood samples on different occasions. There are no fixed timing period. Blood samples are used to determine metformin concentrations, glycosylated haemoglobin (HbA1c), creatinine, vitamin B12 and lactic acid concentration. The overall duration of this study is 24 months.
Query!
Intervention code [1]
269301
0
Not applicable
Query!
Comparator / control treatment
Not applicable.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
279538
0
To investigate whether the pharmacokinetics of metformin is different in Australian Aboriginal and Torres Strait Islander patients compared to non-Indigenous Australians.
Query!
Assessment method [1]
279538
0
Query!
Timepoint [1]
279538
0
Data analysis at the end of recruitment.
Query!
Secondary outcome [1]
287867
0
To investigate factors influencing the pharmacokinetics of metformin between Australian Aboriginal patients. This includes the influence of kidney function (creatinine clearance), body size descriptors (weight) and age. These factors will be used as covariates in a population pharmacokinetic model to investigate inter-patient variability in metformin pharmacokinetics.
Query!
Assessment method [1]
287867
0
Query!
Timepoint [1]
287867
0
At the first instance for each patient.
Query!
Eligibility
Key inclusion criteria
Australian Aboriginal or Torres Strait Islander patients with type 2 diabetes and taking metformin.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients unable to provide informed consent to participate in the study.
Query!
Study design
Purpose
Natural history
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
5/08/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment postcode(s) [1]
4422
0
2036
Query!
Recruitment postcode(s) [2]
4423
0
4870
Query!
Funding & Sponsors
Funding source category [1]
269767
0
Government body
Query!
Name [1]
269767
0
ARC Linkage Grant
Query!
Address [1]
269767
0
Level 2, 11 Lancaster Place
Majura Park ACT 2609
AUSTRALIA
Query!
Country [1]
269767
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Prof Richard Day
Query!
Address
Dept of Clinical Pharmacology and Toxicology
Level 2, St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010
Query!
Country
Australia
Query!
Secondary sponsor category [1]
268808
0
None
Query!
Name [1]
268808
0
Query!
Address [1]
268808
0
Query!
Country [1]
268808
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
271724
0
Aboriginal Health and Medical Research Council (AH&MRC) Ethics Committee
Query!
Ethics committee address [1]
271724
0
Level 3, 66 Wentworth Ave Surry Hills NSW 2010
Query!
Ethics committee country [1]
271724
0
Australia
Query!
Date submitted for ethics approval [1]
271724
0
Query!
Approval date [1]
271724
0
27/05/2011
Query!
Ethics approval number [1]
271724
0
1/11/0785
Query!
Ethics committee name [2]
271725
0
Cairns Base Hospital HREC
Query!
Ethics committee address [2]
271725
0
Cairns Base Hospital PO Box 902 Cairns QLD 4870
Query!
Ethics committee country [2]
271725
0
Australia
Query!
Date submitted for ethics approval [2]
271725
0
Query!
Approval date [2]
271725
0
09/05/2011
Query!
Ethics approval number [2]
271725
0
HREC/11/QCH/33-727
Query!
Summary
Brief summary
This study investigates the use of metformin in Australian Aboriginal and Torres Strait Islander patients with type 2 diabetes. The aim of this study is to compare the pharmacokinetics of metformin in Australian Aboriginal and non-Aboriginal Australians patients. It involves obtaining a medical history of the patient and asking patients about their metformin formulation, dose, dosing times and their compliance to the medication.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33095
0
Query!
Address
33095
0
Query!
Country
33095
0
Query!
Phone
33095
0
Query!
Fax
33095
0
Query!
Email
33095
0
Query!
Contact person for public queries
Name
16342
0
Janna Duong
Query!
Address
16342
0
Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010
Query!
Country
16342
0
Australia
Query!
Phone
16342
0
+61 2 8382 2309
Query!
Fax
16342
0
Query!
Email
16342
0
[email protected]
Query!
Contact person for scientific queries
Name
7270
0
Prof Richard Day
Query!
Address
7270
0
Dept of Clinical Pharmacology and Toxicology
Level 2 St Vincent's Hospital
390 Victoria Street
Darlinghurst NSW 2010
Query!
Country
7270
0
Australia
Query!
Phone
7270
0
+61 2 8382 2304
Query!
Fax
7270
0
Query!
Email
7270
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus.
2015
https://dx.doi.org/10.1111/bcp.12525
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF